长春瑞滨联合卡培他滨治疗晚期三阴性乳腺癌的疗效及生存观察

目的观察长春瑞滨联合卡培他滨治疗复发转移性三阴性乳腺癌患者的疗效和生存情况。方法 29例复发转移性三阴性乳腺癌患者接受长春瑞滨联合卡培他滨化疗,一线治疗者11例,二线治疗者18例。长春瑞滨25 mg/m2,静脉滴注,第1天和第8天;卡培他滨825～1000 mg/m2,口服,每天2次,第1～14天,21 d重复。分析患者的疗效和生存情况。结果 29例患者共接受124个周期治疗,中位治疗周期数为4个周期(2～10个周期)。10例患者获得部分缓解(PR),占34.5%(95%CI 18%～51%),13例患者获得稳定(SD),占44.8%(95%CI 28%～62%),其中4例患者稳定维持6个月以上。6例患者获进展(PD),占20.7%(95%CI 7%～35%)。临床获益患者为14例,临床获益率为48.3%(95%CI 31%～66%)。中位疾病进展时间(TTP)为5个月(95%CI 4～6个月),中位总生存期(OS)为12个月(95%CI 6～32个月)。结论长春瑞滨联合卡培他滨方案近期疗效好,不良反应轻,可作为晚期三阴性乳腺癌患者一线或二线治疗的选择。

Vinorelbine combined with capecitabine in triple negative metastatic breast cancer patients

Objective To evaluate the efficacy and safety of combination chemotherapy of vinorelbine and capecitabine as first-or second-line therapy for metastatic triple negative breast cancer(TNBC).Methods Twenty-nine cases of metastatic TNBC patients received vinorelbine 25mg /m 2 on day 1 and day 8,and capecitabine 825-1000 mg/m 2 twice a day on day 1 through 14.Eleven patients received NX as firstline and eighteen as second-line treatment.Response rate and survival was evaluated.Results In total,124 cycles were given.The median number of treatment was 4 cycles(2-10 cycles).The clinical benefit rate was 48.3%(95% CI 31%-66%),PR 34.5%(95% CI 18%-51%),SD 44.8%(95% CI 28% 62%),including 4 patients maintained SD≥6 months,PD 20.7%(95% CI 7%-35%).The median time to progression was 5 months(95% CI 4-6),the median OS was 12 months(95% CI 6-32).Conclusion Combination therapy of vinorelbine and capecitabine is an effective and well tolerated regimen in metastatic TNBC patients.